Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Other Non-Current Assets (2017 - 2025)

Dianthus Therapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $167000.0 for Q3 2025.

  • Quarterly results put Other Non-Current Assets at $167000.0 for Q3 2025, down 96.47% from a year ago — trailing twelve months through Sep 2025 was $167000.0 (down 96.47% YoY), and the annual figure for FY2024 was $9.6 million, up 734.4%.
  • Other Non-Current Assets for Q3 2025 was $167000.0 at Dianthus Therapeutics, down from $231000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for DNTH hit a ceiling of $9.6 million in Q4 2024 and a floor of $60000.0 in Q3 2022.
  • Median Other Non-Current Assets over the past 4 years was $199000.0 (2025), compared with a mean of $1.5 million.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 96.63% in 2023 and later skyrocketed 7186.15% in 2024.
  • Dianthus Therapeutics' Other Non-Current Assets stood at $121000.0 in 2022, then skyrocketed by 853.72% to $1.2 million in 2023, then surged by 734.4% to $9.6 million in 2024, then tumbled by 98.27% to $167000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $167000.0 (Q3 2025), $231000.0 (Q2 2025), and $9.6 million (Q4 2024) per Business Quant data.